当前位置:首页 - 行情中心 - 多瑞医药(301075) - 财务分析 - 利润表

多瑞医药

(301075)

  

流通市值:23.17亿  总市值:32.74亿
流通股本:5660.00万   总股本:8000.00万

利润表

报告期2026-09-302026-06-302026-03-312025-12-31
公司类型通用通用通用通用
一、营业总收入149,010,342.4295,655,393.0832,431,205.53154,176,460.28
  营业收入149,010,342.4295,655,393.0832,431,205.53154,176,460.28
二、营业总成本204,957,790.84137,708,660.1854,224,700.54274,302,230.06
  营业成本129,466,717.5784,938,279.629,986,080.53141,576,096.97
  税金及附加3,002,843.532,105,638.53864,884.273,505,889.71
  销售费用5,753,394.264,371,505.512,531,255.2223,098,323.98
  管理费用38,655,064.0226,228,455.1312,553,612.6256,896,573.23
  研发费用16,752,428.3513,420,527.574,937,772.8432,410,858.18
  财务费用11,327,343.116,644,253.843,351,095.0616,814,487.99
  其中:利息费用11,093,327.056,603,947.793,336,010.6417,936,231.42
  其中:利息收入-31,794.5128,866.0118,980.831,226,644.74
三、其他经营收益
  加:公允价值变动收益---38,583.78
  加:投资收益45,401,368.6140,205,255.59-263,940.04852,610.79
  资产处置收益242,762.47242,762.47-50,476.75-105,451.29
  资产减值损失(新)832,539.11-642,497.9-594,367.33-5,992,360.28
  信用减值损失(新)2,666,171.972,785,739.391,757,506.65-11,837,463.65
  其他收益6,151,831.194,175,826.042,102,566.398,795,778.76
四、营业利润-652,775.074,713,818.49-18,842,206.09-128,374,071.67
  加:营业外收入2,918,905.541,917,901.21118,844.36
  减:营业外支出395,527.07383,793.11109,759.173,002,204.39
五、利润总额1,870,603.46,247,926.59-18,951,964.26-131,357,431.7
  减:所得税费用3,076,520.013,007,260.0862,272.791,043,958.53
六、净利润-1,205,916.613,240,666.51-19,014,237.05-132,401,390.23
(一)按经营持续性分类
  持续经营净利润-1,205,916.613,240,666.51-19,014,237.05-132,401,390.23
(二)按所有权归属分类
  归属于母公司股东的净利润8,560,828.5311,529,388.32-13,967,969.05-102,169,763.37
  少数股东损益-9,766,745.14-8,288,721.81-5,046,268-30,231,626.86
  扣除非经常损益后的净利润-43,526,518-33,437,648.16-14,447,006.27-107,047,608.69
七、每股收益
  (一)基本每股收益0.110.15-0.18-1.29
  (二)稀释每股收益0.110.15-0.18-1.29
八、其他综合收益-200,000--
  归属于母公司股东的其他综合收益-200,000--
九、综合收益总额-1,205,916.613,440,666.51-19,014,237.05-132,401,390.23
  归属于母公司股东的综合收益总额8,560,828.5311,729,388.32-13,967,969.05-102,169,763.37
  归属于少数股东的综合收益总额-9,766,745.14-8,288,721.81-5,046,268-30,231,626.86
公告日期2026-10-292026-08-262026-04-292026-04-29
审计意见(境内)标准无保留意见
TOP↑